Address: 1715,CHINA WORLD TOWER 1
No. 1 JIAN GUO MEN WAI AVENUE
100004 BEIJING
China (PRC)
Tel: +86 10 65052280
Web: http://www.solvayasiapacific.com/EN/SolvayInAsiaPacific/china/china.aspx
Solvay S.A. is a Belgian chemical and pharmaceutical company. It was founded in 1863 by Ernest Solvay to produce sodium carbonate by the solvay process. Since then the company has diversified to three major sectors of activity: pharmaceuticals, chemicals and plastics.
Solvay (Shanghai) Co., Ltd., a wholly owned subsidiary of Solvay in China is a marketing and sales operations of the main office. The pharmaceutical branch started their operations 11 years ago and currently has more than 200 employees, respectively, in Beijing, Shanghai, Guangzhou and Nanjing.
Pharmaceuticals
The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its…
Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), picks…
The following is an overview from Accestra Consulting* of Part 1 of China’s Center for Drug Evaluation (CDE)’s…
The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli…
In a comprehensive new piece, European Patent Attorney André Bourgouin and Adjunct Professor at CEIBS Eric…
In a big career move on a personal level and a sign of China’s continuing significance to global pharma, Hong…
The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant…
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further…
The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta;…
MSD, which has had a presence in China since 1990, recently appointed Belgian national Anna van Acker to lead its…
Writing in the June edition of DIA’s Global Forum magazine, Harbour BioMed’s Fang Zhou, in conversation…
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs…
